Bayer Research and Development Expenses 2012-2025 | BAYRY
Bayer annual/quarterly research and development expenses history and growth rate from 2012 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Bayer research and development expenses for the quarter ending December 31, 2025 were $1.642B, a 23.07% decline year-over-year.
- Bayer research and development expenses for the twelve months ending December 31, 2025 were $6.527B, a 2.85% decline year-over-year.
- Bayer annual research and development expenses for 2025 were $6.527B, a 2.85% decline from 2024.
- Bayer annual research and development expenses for 2024 were $6.719B, a 15.58% increase from 2023.
- Bayer annual research and development expenses for 2023 were $5.813B, a 16.05% decline from 2022.
|
Bayer Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $6,527 |
| 2024 | $6,719 |
| 2023 | $5,813 |
| 2022 | $6,924 |
| 2021 | $6,403 |
| 2020 | $8,140 |
| 2019 | $5,983 |
| 2018 | $6,196 |
| 2017 | $5,091 |
| 2016 | $5,163 |
| 2015 | $4,754 |
| 2014 | $4,751 |
| 2013 | $4,237 |
| 2012 | $3,875 |
| 2011 | $4,084 |
|
Bayer Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025-12-31 | $1,642 |
| 2025-09-30 | $1,751 |
| 2025-06-30 | $1,598 |
| 2025-03-31 | $1,536 |
| 2024-12-31 | $2,134 |
| 2024-09-30 | $1,714 |
| 2024-06-30 | $1,322 |
| 2024-03-31 | $1,548 |
| 2023-12-31 | $1,153 |
| 2023-09-30 | $1,635 |
| 2023-06-30 | $1,339 |
| 2023-03-31 | $1,686 |
| 2022-12-31 | $1,653 |
| 2022-09-30 | $1,587 |
| 2022-06-30 | $2,052 |
| 2022-03-31 | $1,632 |
| 2021-12-31 | $1,141 |
| 2021-09-30 | $1,844 |
| 2021-06-30 | $1,974 |
| 2021-03-31 | $1,444 |
| 2020-12-31 | $1,484 |
| 2020-09-30 | $3,935 |
| 2020-06-30 | $1,285 |
| 2020-03-31 | $1,436 |
| 2019-12-31 | $1,488 |
| 2019-09-30 | $1,437 |
| 2019-06-30 | $1,519 |
| 2019-03-31 | $1,540 |
| 2018-12-31 | $2,041 |
| 2018-09-30 | $1,372 |
| 2018-06-30 | $1,504 |
| 2018-03-31 | $1,278 |
| 2017-12-31 | $1,359 |
| 2017-09-30 | $1,268 |
| 2017-06-30 | $1,281 |
| 2017-03-31 | $1,182 |
| 2016-12-31 | $1,419 |
| 2016-09-30 | $1,252 |
| 2016-06-30 | $1,267 |
| 2016-03-31 | $1,225 |
| 2015-12-31 | $1,370 |
| 2015-09-30 | $1,158 |
| 2015-06-30 | $1,146 |
| 2015-03-31 | $1,079 |
| 2014-12-31 | $1,299 |
| 2014-09-30 | $1,162 |
| 2014-06-30 | $1,166 |
| 2014-03-31 | $1,124 |
| 2013-12-31 | $1,236 |
| 2013-09-30 | $1,035 |
| 2013-06-30 | $1,012 |
| 2013-03-31 | $955 |
| 2012-12-31 | $1,066 |
| 2012-09-30 | $927 |
| 2012-06-30 | $965 |
| 2012-03-31 | $916 |
| 2011-12-31 | $1,052 |
| 2011-09-30 | $978 |
| 2011-06-30 | $1,046 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |